Paper - WANFANG MED ONLINE

You Position: Home > Paper

胶质母细胞瘤免疫治疗研究进展

( views:58, downloads:372 )

Author:: No author available

Journal Title:: National Medical Journal of China

Issue:: 11

DOI:: 10.3760/cma.j.issn.0376-2491.2015.11.019

Key Word:: No keyword available

Abstract：多形性胶质母细胞瘤(GBM)是成人中最常见的原发颅脑肿瘤,约占原发性颅脑肿瘤的一半[1].尽管应用手术、放疗、化疗等综合治疗,胶质母细胞瘤患者的预后仍不理想,中位生存期仅14.6个月,5年生存率少于10％[2-3].近几年肿瘤免疫治疗快速发展,相关临床试验取得了令人振奋的结果,2010年靶向前列腺酸性磷酸酶的疫苗Sipuleucel-T、免疫抑制靶点CTLA-4的人源单克隆抗体ipilimumab分别获批获用于前列腺癌及进展期黑色素瘤的治疗[4-5].同样,免疫治疗在胶质瘤的临床及临床前期研究中也显示出良好的疗效,有望成为手术、放疗、化疗等治疗之外新的治疗手段.

Reference

[1]崔儒涛,王宝恩,丁惠国,等.Usefulness of determining a protein induced by vitamin Kabsencein detection of hepatocellular carcinoma[J].2002,(1).
[2]Crough,T.,Beagley,L.,Khanna,R.,etc.Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme[J].2012,90(9).
[3]Indro Chakrabarti,Myles Cockburn,Wendy Cozen,etc.A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999[J].2005,104(12).
[4]Philip W. Kantoff,Celestia S. Higano,Neal D. Shore,etc.Sipuleucel-T Immunotherapy for Castration-ResistantProstate Cancer[J].2010,363(5).
[5]Elodie, Vauleon,Tony, Avril,Brigitte, Collet,etc.Overview of cellular immunotherapy for patients with glioblastoma.[J].2010,2010.
[6]John H. Sampson,Henry S. Friedman,Mark R. Gilbert,etc.Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvlll-expressing tumor cells in patients with glioblastoma[J].2011,13(3).
[7]Stupp R,Mason WP,van den Bent MJ,etc.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.[J].2005,352(10).
[8]Hodi FS,O'Day SJ,McDermott DF,etc.Improved survival with ipilimumab in patients with metastatic melanoma.[J].2010,363(8).
[9]Liu C,Hwu P,Yang Y,etc.Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses.[J].2010,16(22).
[10]A, Sehgal,M S, Berger.Basic concepts of immunology and neuroimmunology.[J].2000,9(6).
[11]Brahmer JR,Drake CG,Wollner I,etc.Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.[J].2010,28(19).
[12]Jehad, Charo,Steven E, Finkelstein,Navrose, Grewal,etc.Bcl-2 overexpression enhances tumor-specific T-cell survival.[J].2005,65.
[13]Sampson,J.H.,Choi,B.D.,Sanchez-Perez,L.,etc.EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss[J].2014,20(4).
[14]Marco L, Davila,Isabelle, Riviere,Xiuyan, Wang,etc.Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.[J].2014,6.
[15]Sherry,R.M.,Hughes,M.S.,Rosenberg,S.A.,etc.CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma[J].2012,18(7).
[16]W. F. Hickey,B. L. Hsu,H. Kimura.T-lymphocyte entry into the central nervous system[J].1991,28(2).
[17]Choi,B.D.,Suryadevara,C.M.,Gedeon,P.C.,etc.Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma[J].2014,21(1).
[18]Stupp R,Hegi ME,Mason WP,etc.Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.[J].2009,10(5).
[19]Orin Bloch,Courtney A. Crane,Yelena Fuks,etc.Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase Ⅱ, single-arm trial[J].2014,16(2).
[20]Peter E, Fecci,Duane A, Mitchell,John F, Whitesides,etc.Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.[J].2006,66(6).
[21]Tambuyzer BR,Ponsaerts P,Nouwen EJ.Microglia: gatekeepers of central nervous system immunology.[J].2009,85(3).
[22]Topalian,S.L.,Drake,C.G.,Pardoll,D.M..Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity[J].2012,24(2).
[23]Fadul CE,Fisher JL,Hampton TH,etc.Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.[J].2011,34(4).
[24]See,A.P.,Albesiano,E.,Mathios,D.,etc.Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas[J].2013,86(2).
[25]Dixit,S..Immunotherapy for high-grade glioma[J].2014,10(6).
[26]Blandford,L.E.,Mcnulty,S.,Baschieri,S.,etc.Heat-shock proteins as dendritic cell-targeting vaccines - getting warmer[J].2013,139(4).